Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Sana Biotechnology Inc — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $81.26 (market cap $2.06B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Global X Robo Global Robotics & Automation ETF is far larger — about 2.5× Sana Biotechnology Inc's market cap, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 36 Days and Sana Biotechnology Inc for 23 Days on average.
| ROBO | SANA | |
|---|---|---|
Market Cap | $2.06B | $836.71M |
Volume | 148,111 | 4,507,444 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $5.92 |
52-Week Low | $63.04 | $2.68 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO trades at $81.26, down 0.68% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong institutional interest in robotics and AI themes, with recent news highlighting accelerating adoption across manufacturing, healthcare, and military applications. Financial ratios are unavailable in the current dataset.
The robotics sector offers long-term growth potential amid labor shortages and AI integration, though high RSI levels suggest near-term overbought conditions. Key risks include valuation concerns and sector competition, while analyst coverage remains favorable for diversified robotics exposure.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
